Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16622503 | 1.00 | CYP17A1 (0.53) | CYP17A1CYP19A1PRKCASCN1ASCN2A | |
| SCHEMBL19192812 | 1.00 | CYP17A1 (0.53) | CYP17A1CYP19A1PRKCASCN1ASCN2A | |
| SCHEMBL16731832 | 0.84 | CYP17A1 (0.55) | CYP17A1CYP19A1PRKCASCN1ASCN2A | |
| SCHEMBL19475250 | 0.82 | CYP17A1 (0.54) | CYP17A1CYP19A1PRKCASCN1ASCN2A | |
| SCHEMBL16610643 | 0.81 | CYP17A1 (0.53) | CYP17A1CYP19A1PRKCASCN1ASCN2A | |
| SCHEMBL16610640 | 0.81 | CYP17A1 (0.53) | CYP17A1CYP19A1PRKCASCN1ASCN2A | |
| SCHEMBL16610727 | 0.81 | CYP17A1 (0.53) | CYP17A1CYP19A1PRKCASCN1ASCN2A | |
| SCHEMBL10532688 | 0.81 | CYP17A1 (0.53) | CYP17A1CYP19A1PRKCASCN1ASCN2A | |
| SCHEMBL27437173 | 0.79 | CYP17A1 (0.51) | CYP17A1CYP19A1PRKCASCN1ASCN2A | |
| SCHEMBL16731843 | 0.78 | PRKCA (0.51) | CYP17A1CYP19A1PRKCASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2857385-B1 | PRODRUG OF FLUORINE-CONTAINING AMINO ACID | TAISHO PHARMACEUTICAL CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| EP-2857385-A1 | PRODRUG OF FLUORINE-CONTAINING AMINO ACID | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| US-6458780-B1 | IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | CYP17A1 1426/4885CYP19A1 3911/4885PRKCA 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.